Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD

Phase 4 Completed 40 enrolled University of Maryland, College Park Children's National Research Institute · collab McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · collab

Non-randomizedSingle-groupDouble-blindTreatment

Summary

This study involves a 7 week dose-response trial of Concerta™ methylphenidate for mothers of children with ADHD who have ADHD themselves. The aim of this study is to assess the efficacy of Concerta™ in improving adult ADHD symptoms and impairments (primary outcome), as well as observed and reported parenting (secondary outcome). The researchers hypothesize that Concerta™ will significantly decrease mothers ADHD symptoms and impairment, as well as improve observed and reported parenting

Timeline

Start: 2004-12
Primary completion: —
Completion: 2006-12

Outcome

Met primary endpoint

paper CONCLUSIONS: OROS methylphenidate was well tolerated and was associated with significant improvement in maternal ADHD symptoms and parenting. PMID 19192455 ↗

Publications

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. J Clin Psychiatry. 2008 Dec;69(12):1938-47. doi: 10.4088/jcp.v69n1213. Epub 2008 Dec 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylphenidate	Small molecule	36 mg	Oral
Subject	Methylphenidate	Small molecule	54 mg	Oral
Subject	Methylphenidate	Small molecule	72 mg	Oral
Subject	Methylphenidate	Small molecule	90 mg	Oral